Research ArticleNEUROPHARMACOLOGY
An Inverse Agonist Selective for α5 Subunit-Containing GABAA Receptors Enhances Cognition
G. R. Dawson, K. A. Maubach, N. Collinson, M. Cobain, B. J. Everitt, A. M. MacLeod, H. I. Choudhury, L. M. McDonald, G. Pillai, W. Rycroft, A. J. Smith, F. Sternfeld, F. D. Tattersall, K. A. Wafford, D. S. Reynolds, G. R. Seabrook and J. R. Atack
Journal of Pharmacology and Experimental Therapeutics March 2006, 316 (3) 1335-1345; DOI: https://doi.org/10.1124/jpet.105.092320
G. R. Dawson
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom (G.R.D., K.A.M., N.C., A.M.M., H.I.C., L.M.M., G.P., W.R., A.J.S., F.S., F.D.T., K.A.W., D.S.R., J.R.A.); Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom (M.C., B.J.E.); and Merck Research Laboratories, West Point, Pennsylvania (G.R.S.)
K. A. Maubach
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom (G.R.D., K.A.M., N.C., A.M.M., H.I.C., L.M.M., G.P., W.R., A.J.S., F.S., F.D.T., K.A.W., D.S.R., J.R.A.); Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom (M.C., B.J.E.); and Merck Research Laboratories, West Point, Pennsylvania (G.R.S.)
N. Collinson
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom (G.R.D., K.A.M., N.C., A.M.M., H.I.C., L.M.M., G.P., W.R., A.J.S., F.S., F.D.T., K.A.W., D.S.R., J.R.A.); Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom (M.C., B.J.E.); and Merck Research Laboratories, West Point, Pennsylvania (G.R.S.)
M. Cobain
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom (G.R.D., K.A.M., N.C., A.M.M., H.I.C., L.M.M., G.P., W.R., A.J.S., F.S., F.D.T., K.A.W., D.S.R., J.R.A.); Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom (M.C., B.J.E.); and Merck Research Laboratories, West Point, Pennsylvania (G.R.S.)
B. J. Everitt
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom (G.R.D., K.A.M., N.C., A.M.M., H.I.C., L.M.M., G.P., W.R., A.J.S., F.S., F.D.T., K.A.W., D.S.R., J.R.A.); Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom (M.C., B.J.E.); and Merck Research Laboratories, West Point, Pennsylvania (G.R.S.)
A. M. MacLeod
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom (G.R.D., K.A.M., N.C., A.M.M., H.I.C., L.M.M., G.P., W.R., A.J.S., F.S., F.D.T., K.A.W., D.S.R., J.R.A.); Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom (M.C., B.J.E.); and Merck Research Laboratories, West Point, Pennsylvania (G.R.S.)
H. I. Choudhury
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom (G.R.D., K.A.M., N.C., A.M.M., H.I.C., L.M.M., G.P., W.R., A.J.S., F.S., F.D.T., K.A.W., D.S.R., J.R.A.); Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom (M.C., B.J.E.); and Merck Research Laboratories, West Point, Pennsylvania (G.R.S.)
L. M. McDonald
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom (G.R.D., K.A.M., N.C., A.M.M., H.I.C., L.M.M., G.P., W.R., A.J.S., F.S., F.D.T., K.A.W., D.S.R., J.R.A.); Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom (M.C., B.J.E.); and Merck Research Laboratories, West Point, Pennsylvania (G.R.S.)
G. Pillai
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom (G.R.D., K.A.M., N.C., A.M.M., H.I.C., L.M.M., G.P., W.R., A.J.S., F.S., F.D.T., K.A.W., D.S.R., J.R.A.); Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom (M.C., B.J.E.); and Merck Research Laboratories, West Point, Pennsylvania (G.R.S.)
W. Rycroft
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom (G.R.D., K.A.M., N.C., A.M.M., H.I.C., L.M.M., G.P., W.R., A.J.S., F.S., F.D.T., K.A.W., D.S.R., J.R.A.); Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom (M.C., B.J.E.); and Merck Research Laboratories, West Point, Pennsylvania (G.R.S.)
A. J. Smith
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom (G.R.D., K.A.M., N.C., A.M.M., H.I.C., L.M.M., G.P., W.R., A.J.S., F.S., F.D.T., K.A.W., D.S.R., J.R.A.); Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom (M.C., B.J.E.); and Merck Research Laboratories, West Point, Pennsylvania (G.R.S.)
F. Sternfeld
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom (G.R.D., K.A.M., N.C., A.M.M., H.I.C., L.M.M., G.P., W.R., A.J.S., F.S., F.D.T., K.A.W., D.S.R., J.R.A.); Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom (M.C., B.J.E.); and Merck Research Laboratories, West Point, Pennsylvania (G.R.S.)
F. D. Tattersall
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom (G.R.D., K.A.M., N.C., A.M.M., H.I.C., L.M.M., G.P., W.R., A.J.S., F.S., F.D.T., K.A.W., D.S.R., J.R.A.); Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom (M.C., B.J.E.); and Merck Research Laboratories, West Point, Pennsylvania (G.R.S.)
K. A. Wafford
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom (G.R.D., K.A.M., N.C., A.M.M., H.I.C., L.M.M., G.P., W.R., A.J.S., F.S., F.D.T., K.A.W., D.S.R., J.R.A.); Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom (M.C., B.J.E.); and Merck Research Laboratories, West Point, Pennsylvania (G.R.S.)
D. S. Reynolds
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom (G.R.D., K.A.M., N.C., A.M.M., H.I.C., L.M.M., G.P., W.R., A.J.S., F.S., F.D.T., K.A.W., D.S.R., J.R.A.); Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom (M.C., B.J.E.); and Merck Research Laboratories, West Point, Pennsylvania (G.R.S.)
G. R. Seabrook
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom (G.R.D., K.A.M., N.C., A.M.M., H.I.C., L.M.M., G.P., W.R., A.J.S., F.S., F.D.T., K.A.W., D.S.R., J.R.A.); Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom (M.C., B.J.E.); and Merck Research Laboratories, West Point, Pennsylvania (G.R.S.)
J. R. Atack
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom (G.R.D., K.A.M., N.C., A.M.M., H.I.C., L.M.M., G.P., W.R., A.J.S., F.S., F.D.T., K.A.W., D.S.R., J.R.A.); Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom (M.C., B.J.E.); and Merck Research Laboratories, West Point, Pennsylvania (G.R.S.)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleNEUROPHARMACOLOGY
An Inverse Agonist Selective for α5 Subunit-Containing GABAA Receptors Enhances Cognition
G. R. Dawson, K. A. Maubach, N. Collinson, M. Cobain, B. J. Everitt, A. M. MacLeod, H. I. Choudhury, L. M. McDonald, G. Pillai, W. Rycroft, A. J. Smith, F. Sternfeld, F. D. Tattersall, K. A. Wafford, D. S. Reynolds, G. R. Seabrook and J. R. Atack
Journal of Pharmacology and Experimental Therapeutics March 1, 2006, 316 (3) 1335-1345; DOI: https://doi.org/10.1124/jpet.105.092320
Research ArticleNEUROPHARMACOLOGY
An Inverse Agonist Selective for α5 Subunit-Containing GABAA Receptors Enhances Cognition
G. R. Dawson, K. A. Maubach, N. Collinson, M. Cobain, B. J. Everitt, A. M. MacLeod, H. I. Choudhury, L. M. McDonald, G. Pillai, W. Rycroft, A. J. Smith, F. Sternfeld, F. D. Tattersall, K. A. Wafford, D. S. Reynolds, G. R. Seabrook and J. R. Atack
Journal of Pharmacology and Experimental Therapeutics March 1, 2006, 316 (3) 1335-1345; DOI: https://doi.org/10.1124/jpet.105.092320
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement